How AI is transforming drug discovery

Liam Tremble, Principal Scientist at Poolbeg Pharma, is deeply involved in developing innovative treatments for diseases with significant unmet medical needs. His current work spans oncology, infectious diseases, and endocrinology, where he leads drug discovery efforts.

The medtech industry is at a crucial point, experiencing significant growth driven by the Covid-19 pandemic, which spurred a wave of innovation and investment. Though the sector has now returned to pre-pandemic growth trends, this transition

University College Dublin (UCD) has been recognised for leading the way in research collaboration with industry in Ireland, according to Knowledge Transfer Ireland’s latest Annual Knowledge Transfer Survey (AKTS) for 2023. UCD, through its knowledge transfer

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Business & Finance, established in 1964, is celebrating its 60th anniversary this year. To mark this milestone, the publication is conducting a series of Leadership interviews with influential figures shaping Ireland’s corporate landscape. One of these

Artificial intelligence (AI) represents a sophisticated form of machine learning capable of swiftly analysing extensive datasets, uncovering non-obvious patterns, and pinpointing novel disease targets along with potential drugs. AI is increasingly influencing drug development by identifying

Poolbeg Pharma plc, a forward-thinking biopharmaceutical company, has recently garnered attention for its groundbreaking work with POLB001, a novel therapeutic candidate showing significant promise in clinical research. As an emerging player in the pharmaceutical industry, Poolbeg

A unicorn is the title given to a start-up company that achieves a billion-dollar valuation. Newry-based John McEvoy was previously the Global General Counsel at a Dublin-based pharmaceutical company—a job he landed before he was 30—where

The pharmaceutical sector continues to experience robust growth, driven by a surge in innovative research, the advent of advanced technologies, and an increasing global demand for effective healthcare solutions. This dynamic environment is fostering the development

The future of drug discovery and pharmaceutical research is being reshaped by artificial intelligence (AI), heralding a new era of speed, efficiency, and precision. AI’s potential to accelerate drug development, from molecular prediction to optimised design

Poolbeg Pharma, founded by Cathal Friel, operates with a distinct approach to funding and development. Friel, a renowned financier, has a track record of successfully launching and selling companies through Raglan Capital, his private equity vehicle.

Pharmaceutical giants like Merck KGaA are increasingly partnering with AI companies, signaling a trend in the drug development landscape where emerging technologies are adopted to expedite and improve the drug discovery process. AI promises faster and

Poolbeg Pharma plc is dedicated to the development and commercialisation of innovative medicines, particularly those targeting diseases with high unmet medical needs, including rare and orphan diseases. The company’s strategy revolves around developing its promising clinical

GLP-1 (glucagon-like peptide-1) and its receptor agonists (GLP-1RAs) have emerged as a groundbreaking class of drugs in diabetes management, particularly due to their impressive efficacy in reducing obesity, a key factor in type 2 diabetes. Jeremy

The rapid advancement of artificial intelligence (AI) is making significant strides in the pharmaceutical sector. Since its inception, this industry has embraced AI and machine learning, continuing its legacy of innovation. The integration of these technologies

The year 2020 will be remembered for its tragic events, but in its wake, companies like Poolbeg Pharma are leading efforts to prepare for future pandemics. Richard Staines from Optimum Strategic Communications interviewed Jeremy Skillington, the